Santarus 8-K 2005
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 1.01 Entry into a Material Definitive Agreement.
Santarus, Inc. (the "Company") discloses the departure of Bonnie Hepburn, M.D., from her position as Senior Vice President, Drug Development and Chief Medical Officer. Dr. Hepburn will continue her relationship with the Company as a consultant, and David Ballard, M.D., the Company’s Vice President, Medical Affairs, will assume responsibilities for clinical research in addition to his current responsibilities for medical affairs.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.